GO:0035455 response to interferon-alpha: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035455 response to interferon-alpha describes any process that changes a cell or organism's state or activity after an interferon-alpha stimulus, a type I interferon.
• Interferon-alpha responses are cell-type specific: microglia mount a more extensive and divergent transcriptional response than astrocytes, and macrophages show differential metabolic phenotypes after IFN-alpha versus IFN-beta.
• The response is relevant to viral infections, autoimmune disease such as systemic lupus erythematosus, chronic hepatitis B, and several cancers.
• Viruses can actively suppress interferon-alpha responses; Huwe1-mediated Miz1 degradation suppresses IFN-alpha and IFN-gamma responses and promotes SARS-CoV-2 replication.
• Clinical response to interferon-alpha therapy has been linked to recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B and to viral genotype, such as precore mutant strains.
• CRISPR knockout, point-mutation, knock-in, overexpression and library screening enable causal dissection of genes in the response to interferon-alpha.
Description
GO:0035455 response to interferon-alpha is a Gene Ontology biological process term that captures any change in the state or activity of a cell or organism, including movement, secretion, enzyme production, and gene expression, that results from an interferon-alpha stimulus. Interferon-alpha is a type I interferon and a central cytokine of antiviral defense and immune regulation. Because the term is defined by the stimulus rather than by a single pathway, it encompasses receptor-proximal signaling, transcriptional reprogramming, metabolic shifts, and cell-type-specific effector outputs. Understanding this process matters for researchers because interferon-alpha responses determine outcomes in viral infection, autoimmunity, and cancer therapy. For example, suppression of interferon-alpha and interferon-gamma responses by Huwe1-mediated Miz1 degradation promotes SARS-CoV-2 replication, showing that the pathway is a host-virus battleground. In the clinic, response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B, and response differs in chronic hepatitis B with and without precore mutant strains. Interferon-alpha also has therapeutic relevance in aggressive systemic mastocytosis and in pancreatic cancer cells exposed to ionizing radiation. The response is not uniform across cell types: microglia have a more extensive and divergent response to interferon-alpha compared with astrocytes, and interferon-alpha and interferon-beta induce differential transcriptional and functional metabolic phenotypes in human macrophages, including blunting of glycolysis in response to antigenic stimuli. These findings make GO:0035455 a rich framework for mechanistic, translational, and single-cell studies.
response to interferon-alpha At A Glance
| GO ID | GO:0035455 |
|---|---|
| GO term | response to interferon-alpha |
| Ontology | biological_process |
| Synonym | response to interferon alfa-n1; response to interferon alfa-n3; response to leukocyte interferon; response to lymphoblast interferon; response to lymphoblastoid interferon |
| Major function | Mediates cellular and organismal changes after interferon-alpha stimulation, including gene expression, secretion, movement, and enzyme production |
| Stimulus | Interferon-alpha, a type I interferon |
| Cell-type specificity | Microglia show a more extensive and divergent response than astrocytes; macrophages show differential metabolic phenotypes after IFN-alpha versus IFN-beta |
| Disease relevance | Systemic lupus erythematosus, chronic hepatitis B, aggressive systemic mastocytosis, pancreatic cancer, and SARS-CoV-2 infection |
| Research methods | Transcriptomics, metabolic assays, cytokine profiling, and CRISPR-based perturbation of candidate genes |
What Is GO:0035455?
In plain terms, GO:0035455 response to interferon-alpha is the collection of cellular and organismal changes triggered by interferon-alpha. The QuickGO definition states that it is any process that results in a change in state or activity of a cell or an organism, in terms of movement, secretion, enzyme production, gene expression, and similar outputs, as a result of an interferon-alpha stimulus. Interferon-alpha is a type I interferon. The term is a biological process and includes synonyms such as response to interferon alfa-n1, response to interferon alfa-n3, response to leukocyte interferon, response to lymphoblast interferon, and response to lymphoblastoid interferon. It is therefore broader than a single signaling cascade and can include transcriptional, metabolic, and functional reprogramming observed in microglia, astrocytes, macrophages, and other cell types.
Why Is response to interferon-alpha Important in Cell Biology?
GO:0035455 response to interferon-alpha is important because interferon-alpha sits at the intersection of antiviral immunity, autoimmunity, and cancer biology, and the response to it can determine whether a cell controls a pathogen or whether a virus escapes. The term also has direct clinical translation: response to interferon-alpha therapy correlates with plasmacytoid dendritic cell recovery in pediatric chronic hepatitis B, varies with precore mutant status, and is used in diseases such as aggressive systemic mastocytosis and in experimental pancreatic cancer settings. Because the response is highly cell-type specific, with microglia and astrocytes diverging substantially and macrophages showing distinct metabolic reprogramming, mapping the genes and mechanisms within GO:0035455 is essential for interpreting disease and designing interventions.
• Defines the host response to a major type I interferon used in antiviral and immunomodulatory therapy.
• Relevant to viral pathogenesis, including SARS-CoV-2, where suppression of IFN-alpha and IFN-gamma responses promotes replication.
• Central to autoimmune disease biology such as systemic lupus erythematosus.
• Predicts clinical outcomes in chronic hepatitis B, including correlation with plasmacytoid dendritic cell recovery and precore mutant status.
• Has therapeutic use in aggressive systemic mastocytosis.
• Studied in pancreatic cancer cells with ionizing radiation.
• Shows strong cell-type specificity in the central nervous system, with microglia responding more extensively than astrocytes.
• Involves metabolic reprogramming in human macrophages, including blunting of glycolysis after antigenic stimuli.
• Provides a framework for CRISPR screens to identify causal genes in interferon-alpha response.
• Supports biomarker and drug-target discovery across infection, autoimmunity, and oncology.
What Happens During response to interferon-alpha?
Interferon-alpha recognition and early signaling
In simple terms: The cell first senses interferon-alpha and switches on an antiviral program.
The response begins when a cell receives an interferon-alpha stimulus, a type I interferon, and changes its state or activity, including gene expression, secretion, and enzyme production. This early phase is best understood as a stimulus-defined process rather than a single linear pathway, and it can differ by cell type; for example, microglia have a more extensive and divergent response to interferon-alpha compared with astrocytes. In macrophages, interferon-alpha and interferon-beta induce differential transcriptional and functional metabolic phenotypes, indicating that the identity of the type I interferon shapes the early response.
Transcriptional reprogramming and cell-type divergence
In simple terms: Different cells turn on different sets of genes after seeing interferon-alpha.
A major output of GO:0035455 is altered gene expression. Microglia display a more extensive and divergent transcriptional response to interferon-alpha than astrocytes, showing that the same stimulus can produce cell-type-specific programs. In human macrophages, interferon-alpha and interferon-beta induce differential transcriptional and functional metabolic phenotypes, meaning the response includes not only immune genes but also metabolic genes. These observations support the view that GO:0035455 encompasses broad reprogramming rather than a fixed gene set.
Metabolic and functional consequences
In simple terms: Interferon-alpha changes how cells use energy and respond to further triggers.
Interferon-alpha responses include functional metabolic changes. In human macrophages, interferon-alpha and interferon-beta blunt glycolysis in response to antigenic stimuli, linking the response to immunometabolism. This metabolic dimension is part of the change in state or activity described by GO:0035455 and can influence how cells respond to subsequent challenges.
Viral evasion and suppression of the response
In simple terms: Some viruses try to shut down the interferon-alpha response to survive.
The response to interferon-alpha can be actively suppressed by pathogens. Huwe1-mediated Miz1 degradation suppresses interferon-alpha and interferon-gamma responses and promotes SARS-CoV-2 replication, demonstrating that interfering with GO:0035455-related processes can favor viral replication. This makes the pathway a host-directed target for antiviral research.
Clinical and therapeutic readouts
In simple terms: Doctors can measure how well a patient responds to interferon-alpha treatment.
The response to interferon-alpha has clinical readouts. Response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B, and response differs in chronic hepatitis B with and without precore mutant strains. Interferon-alpha therapy is also used in aggressive systemic mastocytosis, and pancreatic cancer cells have been studied after treatment with interferon-alpha or beta and co-exposure to ionizing radiation. These examples show how GO:0035455 connects mechanism to patient outcomes.
Key Genes Involved in GO:0035455 response to interferon-alpha
The following genes and proteins are experimentally implicated in interferon-alpha responses, including viral suppression, cell-type-specific transcriptional programs, metabolic reprogramming, and clinical response to therapy.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HUWE1 | Mediates Miz1 degradation and suppresses interferon-alpha and interferon-gamma responses | Promotes SARS-CoV-2 replication when active; candidate antiviral target |
| MIZ1 | Transcription factor degraded by Huwe1, affecting interferon responses | Links ubiquitin-proteasome regulation to IFN-alpha suppression |
| IFNA | Encodes interferon-alpha, the type I interferon stimulus | Defines the stimulus for GO:0035455 |
| IFNB | Encodes interferon-beta, a related type I interferon | Used to compare differential responses with IFN-alpha in macrophages |
| STAT1 | Canonical type I interferon signaling transcription factor | Central to interferon-stimulated gene induction; studied in microglia and astrocytes |
| STAT2 | Canonical type I interferon signaling transcription factor | Part of the type I interferon transcriptional complex |
| IRF9 | Forms the ISGF3 complex with STAT1 and STAT2 | Mediates interferon-stimulated gene transcription |
| ISG15 | Interferon-stimulated gene and ubiquitin-like modifier | Readout of interferon-alpha response |
| MX1 | Interferon-induced antiviral GTPase | Common interferon-stimulated gene readout |
| OAS1 | Interferon-induced antiviral enzyme | Common interferon-stimulated gene readout |
| IFIT1 | Interferon-induced protein with tetratricopeptide repeats | Common interferon-stimulated gene readout |
| CXCL10 | Interferon-induced chemokine | Marker of interferon-alpha response in immune cells |
| PDC markers (e.g., CLEC4C) | Plasmacytoid dendritic cell markers | Recovery of blood plasmacytoid dendritic cells correlates with interferon-alpha treatment response |
| Precore/core region of HBV | Viral genotype influences interferon-alpha response | Precore mutant status affects response in chronic hepatitis B |
| KIT | Receptor tyrosine kinase relevant to systemic mastocytosis | Disease context for interferon-alpha therapy |
| Glycolysis genes (e.g., HK2, PFKP) | Metabolic reprogramming after IFN-alpha or IFN-beta | Blunting of glycolysis in macrophages after antigenic stimuli |
How Is response to interferon-alpha Regulated?
The response to interferon-alpha is regulated at multiple levels. Pathogen-encoded or host factors can suppress it; Huwe1-mediated Miz1 degradation suppresses interferon-alpha and interferon-gamma responses and promotes SARS-CoV-2 replication. Cell identity strongly influences the response, as microglia have a more extensive and divergent response to interferon-alpha compared with astrocytes. The type I interferon itself matters: interferon-alpha and interferon-beta induce differential transcriptional and functional metabolic phenotypes in human macrophages and blunt glycolysis in response to antigenic stimuli. Clinically, the response is modulated by host immune recovery, since response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B, and by viral genotype, since response differs in chronic hepatitis B with and without precore mutant strains.
response to interferon-alpha and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HUWE1 | SARS-CoV-2 replication via suppression of IFN-alpha and IFN-gamma responses | Knockout or point-mutation in airway epithelial cells followed by SARS-CoV-2 infection |
| MIZ1 | Interferon response suppression downstream of Huwe1 | Knock-in of degradation-resistant Miz1 to test IFN-alpha response |
| IFNA | Systemic lupus erythematosus and antiviral immunity | Overexpression or reporter knock-in in immune cell lines |
| CLEC4C/PDC markers | Chronic hepatitis B treatment response | Patient-derived plasmacytoid dendritic cell assays |
| HBV precore/core | Chronic hepatitis B interferon-alpha response | HBV genotype-specific infection models |
Viral infection and SARS-CoV-2
Interferon-alpha responses are a first line of antiviral defense, and viruses can counteract them. Huwe1-mediated Miz1 degradation suppresses interferon-alpha and interferon-gamma responses and promotes SARS-CoV-2 replication, identifying the pathway as a host-virus interface. In chronic hepatitis B, response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children, and response differs in patients with and without precore mutant strains.
Autoimmunity and systemic lupus erythematosus
Interferon-alpha is strongly implicated in systemic lupus erythematosus, where it contributes to immune dysregulation and disease activity. Because GO:0035455 describes the cellular response to interferon-alpha, it provides a framework for understanding how type I interferon signals drive autoimmune pathology.
Cancer and therapeutic modulation
Interferon-alpha has therapeutic roles in hematologic and solid tumors. It has been used with prednisolone in aggressive systemic mastocytosis, with reported responses in a case series. In pancreatic cancer cells, treatment with interferon-alpha or beta and co-exposure to ionizing radiation has been studied to understand radiosensitization and cellular response.
Central nervous system and cell-type-specific responses
In the central nervous system, microglia have a more extensive and divergent response to interferon-alpha compared with astrocytes, suggesting that interferon-alpha responses may contribute to neuroimmune and neurodegenerative processes in a cell-type-specific manner. This has implications for diseases where type I interferon signaling is dysregulated.
From response to interferon-alpha-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene suppress interferon-alpha response? | CRISPR knockout in a responsive cell line followed by IFN-alpha stimulation and ISG readout |
| Does a specific amino acid change alter IFN-alpha signaling? | Point-mutation knock-in of the candidate residue |
| Can a tagged protein be tracked after IFN-alpha stimulation? | Tagged knock-in for imaging or immunoprecipitation |
| Does overexpression of a gene blunt or enhance the response? | Overexpression cell model with IFN-alpha treatment and transcriptomics |
| Which genes are required for cell-type-specific IFN-alpha responses? | CRISPR library screening in microglia-like versus astrocyte-like cells |
| How does IFN-alpha alter metabolism? | Metabolic assays in macrophages after IFN-alpha or IFN-beta treatment |
How to Study the response to interferon-alpha Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes after IFN-alpha | Define cell-type-specific response programs |
| Metabolic flux assays | Glycolysis and metabolic phenotype | Test immunometabolic effects of IFN-alpha |
| CRISPR knockout | Loss-of-function effect on IFN-alpha response | Identify causal genes |
| CRISPR point mutation | Effect of a specific residue | Dissect signaling domains |
| Tagged knock-in | Protein localization and interactions | Track candidate proteins after IFN-alpha |
| Overexpression | Gain-of-function effect | Test whether a gene blunts or enhances response |
| Viral infection assays | Viral replication under IFN-alpha pressure | Link host genes to SARS-CoV-2 or HBV outcomes |
| Flow cytometry | Plasmacytoid dendritic cell recovery | Monitor clinical response to IFN-alpha therapy |
Transcriptomic profiling of interferon-alpha responses
RNA sequencing after interferon-alpha stimulation is a primary method to define the gene expression changes that constitute GO:0035455. This approach has been used to show that microglia have a more extensive and divergent response to interferon-alpha compared with astrocytes and that interferon-alpha and interferon-beta induce differential transcriptional phenotypes in human macrophages.
Metabolic and functional assays
Because interferon-alpha responses include functional metabolic changes, assays such as glycolysis measurements are informative. In human macrophages, interferon-alpha and interferon-beta blunt glycolysis in response to antigenic stimuli, demonstrating that metabolic readouts complement transcriptional profiling.
Viral infection and perturbation models
Infection models can test whether a gene suppresses or promotes the interferon-alpha response. Huwe1-mediated Miz1 degradation suppresses interferon-alpha and interferon-gamma responses and promotes SARS-CoV-2 replication, illustrating how loss- and gain-of-function experiments link molecular mechanisms to viral outcomes.
Clinical immune monitoring
Clinical studies can measure the response to interferon-alpha therapy. Recovery of blood plasmacytoid dendritic cells correlates with response to interferon-alpha treatment in children with chronic hepatitis B, and response differs with precore mutant status. These readouts help translate GO:0035455 biology into patient stratification.
How CRISPR Can Be Used to Study GO:0035455 response to interferon-alpha
Knockout
CRISPR knockout is used to remove a candidate gene and test whether the interferon-alpha response is enhanced or suppressed. For example, knocking out a suppressor such as HUWE1 would be predicted to restore interferon-alpha and interferon-gamma responses and limit SARS-CoV-2 replication, based on the finding that Huwe1-mediated Miz1 degradation suppresses these responses. Knockout models are also useful for validating cell-type-specific dependencies in microglia-like and astrocyte-like cells.
Point Mutation
Point-mutation knock-in allows precise testing of residues required for interferon-alpha response. This is valuable for dissecting domains in signaling proteins or viral factors, and for modeling naturally occurring variants that alter response, such as HBV precore mutations associated with differential interferon-alpha treatment response.
Knock-in
Knock-in of tags, reporters, or disease variants enables tracking and functional analysis of genes in GO:0035455. Tagged knock-in can reveal localization and interaction dynamics after interferon-alpha stimulation, while knock-in of degradation-resistant alleles can test stability-dependent regulation such as Miz1 turnover.
Overexpression
Overexpression models test gain-of-function effects on the interferon-alpha response. They are useful for asking whether a gene blunts or enhances transcriptional and metabolic outputs, as seen in studies comparing interferon-alpha and interferon-beta effects in macrophages, and for validating therapeutic targets in cancer cells treated with interferon-alpha.
How EDITGENE Supports response to interferon-alpha Research
Researchers studying response to interferon-alpha-related genes often need to determine whether a candidate gene is causally involved in the response or merely correlated with it. CRISPR-based perturbation provides that causal link, and EDITGENE offers end-to-end cell model generation and screening services tailored to GO:0035455 biology.
Contact EDITGENE today to design your custom CRISPR model for response to interferon-alpha research.
Frequently Asked Questions About response to interferon-alpha
What is GO:0035455 response to interferon-alpha?
GO:0035455 is a Gene Ontology biological process term for any process that changes a cell or organism's state or activity, such as movement, secretion, enzyme production, or gene expression, as a result of an interferon-alpha stimulus; interferon-alpha is a type I interferon.
What genes are involved in response to interferon-alpha?
Genes and proteins implicated include HUWE1 and MIZ1 in viral suppression of interferon responses, type I interferon genes such as IFNA and IFNB, and interferon-stimulated genes used as readouts in microglia and astrocytes.
How does interferon-alpha affect microglia versus astrocytes?
Microglia have a more extensive and divergent response to interferon-alpha compared with astrocytes, indicating strong cell-type specificity.
Does interferon-alpha differ from interferon-beta in macrophages?
Yes, interferon-alpha and interferon-beta induce differential transcriptional and functional metabolic phenotypes in human macrophages and blunt glycolysis in response to antigenic stimuli.
How does SARS-CoV-2 evade interferon-alpha responses?
Huwe1-mediated Miz1 degradation suppresses interferon-alpha and interferon-gamma responses and promotes SARS-CoV-2 replication.
What is the clinical significance of interferon-alpha response in hepatitis B?
Response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B, and response differs with and without precore mutant strains.
Is interferon-alpha used to treat cancer?
Interferon-alpha has been used with prednisolone in aggressive systemic mastocytosis, and pancreatic cancer cells have been studied after interferon-alpha or beta treatment with ionizing radiation.
What diseases are linked to interferon-alpha?
Interferon-alpha is implicated in systemic lupus erythematosus, chronic hepatitis B, aggressive systemic mastocytosis, pancreatic cancer models, and SARS-CoV-2 infection.
How can CRISPR help study response to interferon-alpha?
CRISPR knockout, point mutation, knock-in, overexpression, and library screening can establish causal roles for candidate genes in the interferon-alpha response.
What methods measure response to interferon-alpha?
RNA-seq, metabolic assays, viral infection assays, flow cytometry for plasmacytoid dendritic cells, and CRISPR perturbation screens are commonly used.
Conclusion
GO:0035455 response to interferon-alpha is a stimulus-defined biological process that spans receptor-proximal signaling, transcriptional reprogramming, metabolic shifts, and clinical outcomes. It is central to antiviral defense, autoimmunity, and cancer therapy, with cell-type-specific behavior in microglia, astrocytes, and macrophages. Viral suppression of the response, such as Huwe1-mediated Miz1 degradation promoting SARS-CoV-2 replication, highlights its importance as a host-virus interface. Clinical studies in chronic hepatitis B and case reports in systemic mastocytosis further connect the pathway to patient care. CRISPR-based models and screening provide the causal evidence needed to move from correlation to mechanism in this pathway.
References
- 1. Arunagiri V et al.. 2024. Suppression of interferon α and γ response by Huwe1-mediated Miz1 degradation promotes SARS-CoV-2 replication.. Front Immunol 15:1388517 PMID: 39034993
- 2. Hauswirth AW et al.. 2004. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.. Leuk Res 28(3):249-57 PMID: 14687620
- 3. Li W et al.. 2018. Microglia have a more extensive and divergent response to interferon-α compared with astrocytes.. Glia 66(10):2058-2078 PMID: 30051922
- 4. Leisching G et al.. 2024. Interferon α and β induce differential transcriptional and functional metabolic phenotypes in human macrophages and blunt glycolysis in response to antigenic stimuli.. Eur J Immunol 54(9):e2451032 PMID: 38993003
- 5. Zhang Z et al.. 2007. Response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B.. J Hepatol 47(6):751-9 PMID: 17920718
- 6. Seo Y et al.. 2004. Response to interferon-alpha in chronic hepatitis B with and without precore mutant strain detected by mutation site-specific assay.. J Clin Gastroenterol 38(5):460-4 PMID: 15100528
- 7. Niewold TB et al.. 2010. Interferon alpha in systemic lupus erythematosus.. J Biomed Biotechnol 2010:948364 PMID: 20652065
- 8. Jöst E et al.. 2010. Response of pancreatic cancer cells treated with interferon-alpha or beta and co-exposed to ionising radiation.. Int J Radiat Biol 86(9):732-41 PMID: 20586542
